Antineoplastics
1
Reactions 1100 - 6 May 2006 S Antineoplastics Drug hypersensitivity: case report A 60-year-old woman experienced drug hypersensitivity during treatment with paclitaxel, carboplatin, doxorubicin and cisplatin for ovarian cancer. The woman underwent a hysterectomy and started treatment with paclitaxel [dosage and duration of treatment not stated]. She subsequently developed severe paclitaxel hypersensitivity with heart arrest. Antineoplastic therapy was then completed with three cycles of carboplatin and cyclophosphamide. Approximately 16 months later, she started treatment with carboplatin [dosage not stated] for tumour progression, but experienced drug hypersensitivity on completion of her second carboplatin cycle. Treatment with doxorubicin 30 mg/m 2 was then initiated, but she developed drug hypersensitivity during the first cycle. The following year she received eight cycles of topotecan for metastatic disease, followed by anastrozole. Approximately 1 year after starting anastrozole, she started treatment with cisplatin 30 mg/m 2 [duration of treatment not stated] for persistent metastatic disease, but subsequently developed drug hypersensitivity. She later completed seven cycles of vinorelbine and three cycles of paclitaxel [abraxane], without incident. Micha JP, et al. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecologic Oncology 100: 437-438, No. 2, Feb 2006 - USA 801039188 1 Reactions 6 May 2006 No. 1100 0114-9954/10/1100-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1100 - 6 May 2006
SAntineoplastics
Drug hypersensitivity: case reportA 60-year-old woman experienced drug hypersensitivity
during treatment with paclitaxel, carboplatin, doxorubicin andcisplatin for ovarian cancer.
The woman underwent a hysterectomy and startedtreatment with paclitaxel [dosage and duration of treatmentnot stated]. She subsequently developed severe paclitaxelhypersensitivity with heart arrest. Antineoplastic therapy wasthen completed with three cycles of carboplatin andcyclophosphamide. Approximately 16 months later, shestarted treatment with carboplatin [dosage not stated] fortumour progression, but experienced drug hypersensitivity oncompletion of her second carboplatin cycle. Treatment withdoxorubicin 30 mg/m2 was then initiated, but she developeddrug hypersensitivity during the first cycle. The following yearshe received eight cycles of topotecan for metastatic disease,followed by anastrozole. Approximately 1 year after startinganastrozole, she started treatment with cisplatin 30 mg/m2
[duration of treatment not stated] for persistent metastaticdisease, but subsequently developed drug hypersensitivity.She later completed seven cycles of vinorelbine and threecycles of paclitaxel [abraxane], without incident.Micha JP, et al. Abraxane in the treatment of ovarian cancer: the absence ofhypersensitivity reactions. Gynecologic Oncology 100: 437-438, No. 2, Feb 2006 -USA 801039188
1
Reactions 6 May 2006 No. 11000114-9954/10/1100-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
